H.C. Wainwright lowered the firm’s price target on BioXcel Therapeutics (BTAI) to $3 from $5 and keeps a Buy rating on the shares. While the company’s prospects “remain intriguing ...

On January 28, 2025, BioXcel Therapeutics, Inc. conducted a special meeting of stockholders to decide on crucial matters. The meeting saw the participation of 30,360,492 shares of common stock ...

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Bioxcel Therapeutics (BTAI – Research Report) yesterday and set a price target of $3.00. The company’s shares closed yesterday ...

BioXcel Therapeutics (BTAI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). NEW HAVEN, Conn., Nov. 22, 2024 (GLOBE ...

BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a pharmaceutical company specializing in drug development with a current market capitalization of $17.2 million, announced on Wednesday the expansion of ...

Three C-level officials at New Haven-based biopharmaceutical company BioXcel Therapeutics Inc. have taken cuts to their cash compensation as the business, which uses artificial intelligence to ...

Insider trading activity involves company insiders, such as executives, directors, and employees, engaging in transactions of their own company's stock. Insiders' buy and sell transactions provide ...